U.S. markets open in 3 hours 57 minutes
  • S&P Futures

    4,470.00
    -4.25 (-0.09%)
     
  • Dow Futures

    34,737.00
    -12.00 (-0.03%)
     
  • Nasdaq Futures

    15,498.00
    -19.75 (-0.13%)
     
  • Russell 2000 Futures

    2,224.00
    -3.90 (-0.18%)
     
  • Crude Oil

    72.13
    -0.48 (-0.66%)
     
  • Gold

    1,766.20
    +9.50 (+0.54%)
     
  • Silver

    23.10
    +0.31 (+1.34%)
     
  • EUR/USD

    1.1781
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.80
    +0.62 (+3.41%)
     
  • GBP/USD

    1.3793
    -0.0004 (-0.03%)
     
  • USD/JPY

    109.9500
    +0.2320 (+0.21%)
     
  • BTC-USD

    47,900.36
    -306.13 (-0.64%)
     
  • CMC Crypto 200

    1,223.84
    -9.45 (-0.77%)
     
  • FTSE 100

    7,039.59
    +12.11 (+0.17%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Pfizer presents results from CAPiTA study evluating Prevenar 13

Pfizer presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults, demonstrating that Prevenar 13 prevented a first episode of vaccine-type community-acquired pneumonia in adults 65 years of age and older, the study’s primary objective. This trial is the first in adults to clearly demonstrate a significant reduction in vaccine-type pneumococcal CAP, and importantly, non-bacteremic/non-invasive vaccine-type pneumococcal CAP.